Long-term effects in people who recovered from COVID-19 infection
Studies samples and health data from adults who recovered from COVID-19 infection.
Plain-language title generated from the registry record
Registry title: Long-term Impact of Infection With Novel Coronavirus (COVID-19)
Key facts
- Where
- San Francisco, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT04362150, who can take part
Where in United States
- Zuckerberg San Francisco General Hospital (ZSFG)San Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT04362150
- Record updated
- 23 July 2026
- Original description
LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.Read full original descriptionShow less
Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study
LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.
Inclusion: Willing and able to provide written informed consent, and; Age >/= 18 years, and; A history of SARS-CoV-2 infection, as evidenced by:; Available laboratory documentation of SARS-CoV-2 RNA positivity on a nucleic acid amplification test or by serologic testing when this becomes available, or; Reference by the participant to a laboratory test performed on respiratory tract secretions or blood, fingerstick, or saliva test that was reported to the participant to be positive for SARS-CoV-2 or COVID-19 infection,; And a period of 21 days or more has elapsed since the first positive test or symptoms preceding the first positive test, whichever is earlier.
Exclusion: Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements or to give informed consent; Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent; Self-reported or documented chronic anemia with hemoglobin < 9 g/dL. Anemia during a preceding acute illness will not be exclusionary.